Table 1.
Baseline demographics and disease characteristics of patients with sJIA and patients with pJIA
| Characteristic | sJIA |
pJIA |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCZ-naive n = 26 |
TCZ-prior n = 25 |
All TCZ n = 51 |
TCZ-naive n = 37 |
TCZ-prior n = 15 |
All TCZ n = 52 |
|||||||
| <30 kg Q10D/Q2W n = 15 | ≥30 kg QW n = 11 | <30 kg Q10D/Q2W n = 10 | ≥30 kg QW n = 15 | <30 kg Q10D/Q2W n = 25 | ≥30 kg QW n = 26 | <30 kg Q3W n = 23 | ≥30 kg Q2W n = 14 | <30 kg Q3W n = 4 | ≥30 kg Q2W n = 11 | <30 kg Q3W n = 27 | ≥30 kg Q2W n = 25 | |
| Age, years, mean (S.D.) | 5.2 (3.0) | 13.1 (3.2) | 4.9 (3.6) | 13.5 (3.2) | 5.1 (3.2) | 13.3 (3.2) | 5.3 (2.1) | 14.9 (2.2) | 6.8 (1.0) | 12.7 (2.9) | 5.5 (2.1) | 13.9 (2.7) |
| Females, n (%) | 7 (46.7) | 6 (54.5) | 6 (60.0) | 10 (66.7) | 13 (52.0) | 16 (61.5) | 14 (60.9) | 10 (71.4) | 4 (100.0) | 8 (72.7) | 18 (66.7) | 18 (72.0) |
| Weight, kg, mean (S.D.) | 19.1 (5.4) | 52.2 (14.3) | 18.1 (6.4) | 51.3 (12.8) | 18.7 (5.7) | 51.7 (13.2) | 19.2 (4.9) | 60.4 (15.1) | 22.2 (1.3) | 51.9 (15.3) | 19.7 (4.7) | 56.7 (15.5) |
| No. of active joints, mean (S.D.) | 11.6 (11.6) | 6.6 (8.1) | 1.3 (1.8) | 1.2 (2.2) | 7.5 (10.3) | 3.5 (6.0) | 9.4 (7.5) | 11.4 (8.5) | 1.3 (1.9) | 7.0 (11.2) | 8.2 (7.5) | 9.5 (9.8) |
| CHAQ-DI score, mean (S.D.) | 1.28 (0.93) | 0.78 (1.00) | 0.28 (0.42) | 0.45 (0.77) | 0.88 (0.90) | 0.59 (0.88) | 0.95 (0.66) | 0.88 (0.70) | 0.50 (0.51) | 0.59 (0.73) | 0.88 (0.65) | 0.76 (0.72) |
| JADAS-71 score, mean (S.D.) | 23.6 (15.6) | 15.9 (12.4) | 3.2 (3.3) | 3.5 (5.2) | 15.5 (15.8) | 8.7 (10.8) | 19.7 (9.8) | 21.0 (9.9) | 5.9 (7.1) | 11.4 (14.6) | 17.6 (10.6) | 16.8 (12.9) |
| Concurrent MTX use, n (%) | 8 (53.3) | 5 (45.5) | 5 (50.0) | 9 (60.0) | 13 (52.0) | 14 (53.8) | 18 (78.3) | 7 (50.0) | 3 (75.0) | 8 (72.7) | 21 (77.8) | 15 (60.0) |
| Concurrent glucocorticoid use, n (%)a | 14 (93.3) | 8 (72.7) | 6 (60.0) | 4 (26.7) | 20 (80.0) | 12 (46.2) | 11 (47.8) | 6 (42.9) | 0 | 6 (54.5) | 11 (40.7) | 12 (48.0) |
| Previous biologic use, n (%) | 4 (26.7) | 8 (72.7) | 10 (100.0) | 15 (100.0) | 14 (56.0) | 23 (88.5) | 6 (26.1) | 10 (71.4) | 4 (100) | 11 (100) | 10 (37.0) | 21 (84.0) |
CHAQ-DI: Childhood HAQ–Disability Index; JADAS-71: Juvenile Arthritis DAS including 71 joints; pJIA: polyarticular JIA; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; Q3W: every 3 weeks; sJIA systemic JIA; TCZ: tocilizumab.
a
Included all prior and concomitant use.